A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
Sandhu et al.,
A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate..,
Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954
Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
risk of death, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%), NNT 3.0.
|
risk of mechanical ventilation, 52.9% lower, RR 0.47, p < 0.001, treatment 16 of 34 (47.1%), control 68 of 68 (100.0%), NNT 1.9.
|
risk of no hospital discharge, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%), NNT 3.0.
|
hospitalization time, 4.5% lower, relative time 0.95, treatment 34, control 78.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sandhu et al., 27 Oct 2020, prospective, USA, peer-reviewed, 4 authors, dosage 1.2mg days 1-3, 0.6mg days 4-15.
Abstract: Hindawi
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2020, Article ID 8865954, 9 pages
https://doi.org/10.1155/2020/8865954
Research Article
A Case Control Study to Evaluate the Impact of Colchicine on
Patients Admitted to the Hospital with Moderate to Severe
COVID-19 Infection
Tegveer Sandhu , Arlene Tieng , Sridhar Chilimuri , and Giovanni Franchin
Department of Internal Medicine, BronxCare Health System, Bronx, NY 10457, USA
Correspondence should be addressed to Tegveer Sandhu; tsandhu@bronxleb.org
Received 30 July 2020; Revised 21 September 2020; Accepted 8 October 2020; Published 27 October 2020
Academic Editor: Aim Hoepelman
Copyright © 2020 Tegveer Sandhu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Colchicine has been used in conditions such as periodic febrile illness, acute pericarditis, and gouty arthritis, all
having a common hyperinflammatory response as seen in moderate to severe forms of coronavirus disease 2019 (COVID-19). This
project was carried out during the rapid surge of cases in New York City, and the goal was to assess the efficacy of colchicine in
treating patients with COVID-19. Methods. Patients admitted to two distinct pulmonary oriented floors of the BronxCare
Hospital Center were compared. Patients on one floor were given colchicine in addition to standard of care, while control patients
from another floor received only standard of care. Patients who had at least two separate timepoint measurements for at least two
out of four serum inflammatory markers (C-reactive protein (CRP), D-dimer, ferritin, or lactate dehydrogenase (LDH)) were
selected for the final comprehensive analysis. Results. An initial analysis performed on all patients, irrespective of the availability of
two timepoint inflammatory markers, revealed a lower mortality (49.1% versus 72.9%, P � 0.002), a lower percentage of intubations (52.8% versus 73.6%, P � 0.006), and a higher discharge rate (50.9% versus 27.1%, P � 0.002), in the patients who
received colchicine. Patients in the final comprehensive analysis groups (34 in the colchicine group and 78 in the control group)
had a similar prevalence of comorbid medical conditions, except for renal failure, which was higher in the control group (65.3%
versus 35.2%, P � 0.015). HTN (71.8% versus 52.9%, P � 0.053) and DM (51.3% versus 32.4%, P � 0.064) were also more
prevalent in the control group, although the difference was not statistically significant. Patients who received colchicine had a
lower mortality than the control group (47.1% versus 80.8%, P � 0.0003), lower rate of intubations (47.1% versus 87.2%,
P < 0.0001), and a higher discharge rate (52.9% versus 19.2%, P � 0.0003). Patients in the colchicine group also showed a more
significant decrease in inflammatory markers for D-dimer (P � 0.037), CRP (P � 0.014), and ferritin (P � 0.012). Conclusions.
Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future
randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit